Kegonsa Seed Fund

NanoMedex Pharmaceuticals

Founders: Nickolaus Gravenstein, Donn Dennis, Tim Morey, Jerome Modell, and Dinesh Shah
Inventors: Nickolaus Gravenstein, Donn Dennis, Tim Morey, Jerome Modell, and Dinesh Shah
Managers: David L. Cooper (CEO), Nate Voss (COO)
Industry: Pharmaceuticals
Established: 2002
Headquarters: Fitchburg, Wisconsin
Website: www.nanomedex.com
Description:

NanoMedex Pharmaceuticals, Inc. uses patented strategies to reformulate fat- or lipid-soluble drugs so they can be dissolved in water and administrated intravenously. Intravenous administration offers a variety of benefits to patients, physicians, and health care providers.

NanoMedex's first product is Microfol™, a new formulation of propofol, a widely used anesthetic.

Investment History:
  • Seed funding was provided by Nickolaus Gravenstein, Donn Dennis, Tim Morey, Jerome Modell, and Dinesh Shah, the company founders.
  • The Kegonsa Seed Fund led the Series A financing round with the Kegonsa Coinvest Fund and current management as investors.

Company Leaders

Nickolaus Gravenstein, M.D., Donn Dennis, M.D., Tim Morey, M.D., Jerome Modell, M.D. and Dinesh Shah, M.D., are the co-founders of NanoMedex Pharmaceuticals, Inc. While employed at the University of Florida-Gainesville, they invented the formulation strategy upon which the company's products are built.

Drs. Gravenstein and Morey continue to serve on NanoMedex's Board of Directors.

David L. Cooper, M.D., Ph.D. is President and CEO of NanoMedex Pharmaceuticals, Inc.

Before joining NanoMedex, David was Chief Medical Officer of Nimblegen, which was recently sold to Roche, and Vice President of Quest Diagnostics. David also provided product development services to the Marshfield Clinic for three years.

Nate Voss is Chief Operating Officer of NanoMedex Pharmaceuticals.

Before joining NanoMedex, Voss worked for Baker Tilly Virchow Krause, where he provided a broad array of financial advisory services, including mergers and acquisitions, debt and equity financing, tax credit financing, and business valuations.